WUMC-Cancer and Leukemia Group B

WUMC-癌症和白血病 B 组

基本信息

批准号：
6887426
负责人：
NANCY L BARTLETT
金额：
$ 32.71万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-05-08 至 2009-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6887426
关键词：
aging antineoplastics breast neoplasms cancer prevention cancer registry /resource cis platinum compound clinical research clinical trial phase I clinical trial phase II clinical trial phase III combination cancer therapy combination chemotherapy cooperative study doxorubicin drug resistance fluorouracil gastrointestinal neoplasms health care cost /financing hormone therapy human subject human therapy evaluation irinotecan leucovorin leukemia lymphoma melanoma neoplasm /cancer chemotherapy neoplasm /cancer diagnosis neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer surgery oncology nursing paclitaxel pathology patient oriented research prostate neoplasms psychological aspect of cancer quality of life respiratory neoplasm tamoxifen thorax neoplasm urinary tract neoplasms

项目摘要

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin's lymphoma, Hodgkin's lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials.

描述（改编自申请人的摘要）：华盛顿大学自1986年以来一直是Calgb的主要成员机构。在过去的五年中，华盛顿大学医学中心（WUMC）的癌症研究计划经历了巨大的增长。圣路易斯最大的医院巴恩斯·犹太医院（Barnes-Jewish Hospital）每年诊断出5400多名癌症患者，并且仍然是密苏里州东南部和伊利诺伊州南部的主要转诊中心。 WUMC的SITEMAN癌症中心（SCC）于2001年8月获得NCI指定的癌症中心地位。SCC开发的基础设施成功地为NCI癌症中心支持拨款而成功地竞争了我们的临床癌症研究所有方面的能力，包括合作小组试验。我们最近扩大机构研究的努力将显着增强我们在下一个赠款周期中为CalgB贡献概念的能力，特别是在血液学恶性肿瘤，胸腔肿瘤学和药物基因组学领域。在1998年至2002年之间，华盛顿大学的医师和研究助理在36个不同的CalgB科学和行政委员会任职。 WUMC研究人员主持了12项CALGB研究，包括非霍奇金淋巴瘤，霍奇金的淋巴瘤，前列腺癌，间皮瘤以及几项药代动力学和药物基因组相关科学研究的II期研究。在发展的最后阶段，还有六项研究。在这一赠款期间，对CALB试验的应计持续增加，从1998年到2001年，每年为治疗和非治疗试验注册了183名患者。从1998年的61例患者的应计增加到2001年的61名患者，根据迄今为止的注册，对CalGB的注册进行了2002年的研究。下一个赠款周期的计划包括1）所有当前所有WUMC研究者的持续参与，2）我们的I期研究人员增加参与的参与，以促进CALGB中的II阶段研究的发展，3）至少五个其他WUMC研究人员参与CALGB活动中的活动，包括对GU癌症的培养基，包括GU癌症的质量，干细胞移植和5），以及5），以及5），以及5），以及5），质量，质量，以及5），以及5），以及5）。应计入CALGB试验的应计，尤其是少数派应计。